SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 67 of 83
Word Count: 1470
Character Count: 9311

Document Content:

the proposed initial public offering does not occur, any retainer balance will be refunded to the extent expenses were not actually incurred in accordance with FINRA Rule 5110(g)(4)(A). estimate that the total expenses of this offering payable by us, excluding the total underwriting discount, will be approximately $ . Discretionary Accounts The underwriters do not intend to confirm sales of the shares offered hereby to any accounts over which they have discretionary authority. Electronic Distribution prospectus in electronic format may be made available on the websites maintained by one or more of the underwriters or selling group members, if any, participating in this offering. The Representative may allocate a number of shares to the underwriters and selling group members, if any, for sale to their online brokerage account holders. Any such allocations for online distributions will be made by the Representative on the same basis as other allocations. Representative’s Warrant

Upon
the closing of this offering, we have agreed to issue to the Representative or its designees a five-year warrant to purchase up to five
percent (5%) of the shares of common stock sold by us in this offering (including any shares of common stock sold pursuant to the exercise
of the underwriters’ over-allotment option) (the “Representative’s Warrant”). The Representative’s Warrant
will be exercisable at a per share exercise price equal to the public offering price per share. The Representative’s Warrant will
be exercisable at any time, and from time to time, in whole or in part, from the first day of the seventh month after the closing of
this offering to the date that is five years from the date of commencement of sales in this offering, in compliance with FINRA Rule 5110.
The Representative’s Warrant is also exercisable on a cashless basis. The registration statement of which this prospectus is a
part also registers the offer and sale of the Representative’s Warrant and the shares of our common stock issuable upon exercise
thereof.

The
Representative’s Warrant has been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to FINRA
Rule 5110. Except as permitted by Rule 5110, the Representative (or permitted assignees under such rule) will not sell, transfer, assign,
pledge, or hypothecate the Representative’s Warrant or the securities underlying the Representative’s Warrant, nor will any
of them engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition
of the Representative’s Warrant or the underlying securities for a period of 180 days from the commencement of sales
under this prospectus.

The
exercise price and number of shares of common stock issuable upon exercise of the Representative’s Warrant may be adjusted in certain
circumstances including in the event of a stock dividend, extraordinary cash dividend or recapitalization, reorganization, merger or
consolidation.

Lock-Up
Agreements

Our
officers and directors and our existing stockholders prior to this offering have agreed not to, without the prior written consent of
the underwriters, directly or indirectly, offer to sell, sell or otherwise transfer or dispose of any shares of our common stock (or
enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person
at any time in the future of shares of our common stock), enter into any swap or other derivatives transaction that transfers to another,
in whole or in part, any of the economic benefits or risks of ownership of shares of common stock, make any demand for or exercise any
right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any of the
shares of common stock or securities convertible into or exercisable or exchangeable for shares of common stock or any other of our securities
or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for a period of six (6) months from the
date of closing of this offering.

Securities
Issuance Standstill

have agreed that for a period of 180 days from the closing of this offering, we will not, without the prior written consent of the Representative,
(a) offer, sell or otherwise transfer or dispose of, directly or indirectly, any shares of our capital stock or any securities convertible
into or exercisable or exchangeable for shares of our capital stock; or (b) file or cause to be filed any registration statement with
the SEC relating to this offering of any shares of our capital stock or any securities convertible into or exercisable or exchangeable
for shares of our capital stock.

Tail
Financing

The
Representative will also be entitled to an aggregate additional fee of seven percent (7%) of the gross proceeds of future financings
and warrants to purchase up to five percent (5%) of the number of securities sold in future financings consummated solely with investors
with whom we have had a conference call or a meeting arranged by the Representative prior to the expiration or termination of the Engagement
Letter; provided that the future financing is consummated at any time within the twelve (12) month period following the earlier to occur
of (i) the expiration or termination of the Engagement Letter or (ii) the closing of this offering.

Right
of First Refusal

have granted the Representative the right to act as lead or joint-lead investment banker, lead or joint book-runner, lead or joint placement
agent and/or investment banker/advisor, for any of our future public and private equity and debt offerings, including all equity linked
financings, during the twelve (12) month period following the completion of this offering in compliance with FINRA Rule 5110(g)(6).

Determination
of Offering Price

Prior
to this offering, there has been no public market for our common stock. The public offering price was negotiated between the Representative
and us. In determining the public offering price of our common stock, the Representative considered:

●	the
history and prospects for the industry in which we compete;

●	our
financial information;

●	the
ability of our management and our business potential and earning prospects;

●	the
prevailing securities markets at the time of this offering; and

●	the
recent market prices of, and the demand for, publicly traded shares of generally comparable
companies, as well as the recent market price of our common stock.

Listing

have applied to have our common stock listed on Nasdaq under the symbol “BVXX”. In order to meet one of the requirements
for listing our common stock on Nasdaq, the underwriters have undertaken to sell lots of 100 or more shares to a minimum of 300 beneficial
holders.

Stabilization

connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids, and purchases to cover positions created by short sales.

●	Stabilizing
transactions permit bids to purchase securities so long as the stabilizing bids do not exceed
a specified maximum and are engaged in for the purpose of preventing or retarding a decline
in the market price of the securities while this offering is in progress.

●	Over-allotment
transactions involve sales by the underwriters of securities in excess of the number of securities
the underwriters are obligated to purchase. This creates a syndicate short position which
may be either a covered short position or a naked short position. In a covered short position,
the number of securities over-allotted by the underwriters is not greater than the number
of securities that they may purchase in the over-allotment option. In a naked short position,
the number of securities involved is greater than the number of securities in the over-allotment
option. The underwriters may close out any short position by exercising their over-allotment
option and/or purchasing securities in the open market.

●	Syndicate
covering transactions involves purchases of securities in the open market after the distribution
has been completed in order to cover syndicate short positions. In determining the source
of securities to close out the short position, the underwriters will consider, among other
things, the price of securities available for purchase in the open market as compared with
the price at which they may purchase securities through exercise of the over-allotment option.
If the underwriters sell more securities than could be covered by exercise of the over-allotment
option and, therefore, have a naked short position, the position can be closed out only by
buying securities in the open market. A naked short position is more likely to be created
if the underwriters are concerned that after pricing there could be downward pressure on
the price of the securities in the open market that could adversely affect investors who
purchase in this offering.

●	Penalty
bids permit the underwriters to reclaim a selling concession from a syndicate member when
the securities originally sold by that syndicate member are purchased in stabilizing or syndicate
covering transactions to cover syndicate short positions.